Characteristics of ruxolitinib discontinuation syndrome in myelofibrosis
Last Updated: Thursday, July 9, 2020
Among patients with myelofibrosis treated with ruxolitinib, ruxolitinib discontinuation syndrome (RDS) occurred in 13.5% of patients, and was severe in only 1.2% of patients. Of the patients who developed RDS, 61.8% experienced mild symptoms, including discomfort related to splenomegaly, fatigue, pruritis, bone pain, and B-symptoms, according to abstract data presented at the 2020 European Hematology Association Annual Congress.
Advertisement
News & Literature Highlights
